MERS- CoV : the global epidemiology - PowerPoint PPT Presentation

mers cov the global epidemiology n.
Skip this Video
Loading SlideShow in 5 Seconds..
MERS- CoV : the global epidemiology PowerPoint Presentation
Download Presentation
MERS- CoV : the global epidemiology

play fullscreen
1 / 20
MERS- CoV : the global epidemiology
Download Presentation
Download Presentation

MERS- CoV : the global epidemiology

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. MERS-CoV: the global epidemiology Republic of Lebanon Ministry of Public Health Epidemiological Surveillance Program May 2014

  2. Sources • WHO: • CDC: • ECDC: • world map:

  3. Outline • Total count • By time • By place • By person • Travel advice

  4. Total count • Since April 2012 to 08 May 2014 • 536 laboratory-confirmed cases of MERS-CoV • including 145 deaths • To date, the affected countries • Middle East; Jordan, Kuwait, Oman, Qatar, Saudi Arabia (KSA), United Arab Emirates (UAE) and Yemen • Africa: Egypt and Tunisia • Europe: France, Germany, Greece, Italy and the United Kingdom • Asia: Malaysia and Philippines • North America: the United States of America (USA). • All of the cases recently reported outside the Middle East recently travelled from countries inside of the Middle East (KSA or UAE). Source: WHO

  5. Time: Epidemic Curves Confirmed cases by country of presumed exposure Source: WHO

  6. Time: Epidemic Curves Confirmed cases by outcome Source: WHO

  7. Time: Epidemic Curves Epidemic Curve by Case-Type (Primary vs. Secondary) Source: WHO

  8. Place: of onset (up to 16May 2014) Source: ECDC

  9. Place: of onset (up to 16May 2014) Source: ECDC

  10. Place: place of exposure Cases by country of probable exposure Source: WHO

  11. Place: place of exposure Source: WHO

  12. Place: place of exposure Source: ECDC

  13. Place: World map Source:

  14. Person • Gender: 66% of cases are male • Median age is 49 years old (range 9 months-94 years old) • Primary < secondary cases

  15. Person Source: ECDC

  16. Person Characteristics of primary vs secondary cases* *Table includes cases with reported information on each variable; 234 cases have missing information about case type Source: WHO

  17. WHO Travel Advice 1 • At this time, the risk to an individual pilgrim of contracting MERS-CoV is considered very low. • WHO does not recommend the application of any travel or trade restrictions or entry screening. • Before departure, pilgrims should be advised: • Pre-existing major medical conditions can increase the likelihood of illness, including MERS-CoV infection, during travel • Pilgrims should consult a health care provider to review the risk and assess whether making the pilgrimage is advisable

  18. WHO Travel Advice 2 • Dissemination of general travel health precautions, which will lower the risk of infection in general. • Specific emphasis should be placed on: • Washing hands often with soap and water , or with hand rub • Adhering to good food-safety practices (avoiding undercooked meat or food prepared under unsanitary conditions, and properly washing fruits and vegetables before eating them) • Maintaining good personal hygiene • Avoiding unnecessary contact with farm, domestic, and wild animals

  19. WHO Travel Advice 3 • Travelers who develop a significant ARI with fever and cough (severe enough to interfere with usual daily activities) should be advised to: • Minimize their contact with others • Adopt cough etiquette: Cover their mouth and nose with a tissue when coughing or sneezing and discard the tissue in the trash after use and wash hands afterwards, or, if this is not possible, to cough or sneeze into upper sleeves of their clothing, but not their hands • Report to the medical staff

  20. WHO Travel Advice 4 • Patients: • Returning pilgrims developing a significant ARI with fever and cough during the two weeks after their return should seek medical attention. • Persons who have had close contact with a pilgrim or traveler with a significant ARI with fever and cough and who themselves develop such an illness should seek medical attention. • Clinicians: • Practitioners and facilities should be alerted to the possibility of MERS-CoV infection in returning pilgrims with ARI, especially those with fever and cough and pulmonary parenchymal disease • If clinical presentation suggests the diagnosis of MERS-CoV, laboratory testing, should be done and infection prevention and control measures implemented.